Caracterización de eventos adversos con Tocilizumab reportados en Bogotá D.C. entre los años 2011 – 2016

The Rheumatoid arthritis is a systemic autoimmune disease, characterized by chronic inflammation, mainly of the joints that produces progressive destruction with different degrees of deformity and functional disability; This disease affects between 0.4% and 1% of the population of Latin America and is much more common in women than in men. Similarly, rheumatoid arthritis occurs most frequently between the ages of 30 to 50 years of age, thus causing reduced work capacity and quality of life. The treatment to be carried out of rheumatoid arthritis, is carried out through the use of disease modifying drugs such as: methotrexate and leflunomide and in case of presenting an inadequate response we proceed with the use of biological agents, which are drugs directed against specific molecules involved in the pathogenesis of the disease such as Rituximab and Tocilizumab. For this reason, the aim of the present research is to characterize the adverse reactions with tocilizumab reported in Bogotá D.C between the years 2011-2016. To this end, a retrospective-documental-cross-sectional design was used, since the information was taken from the database allowed by the national pharmacovigilance program of the Ministry of Health of Bogotá. Where a total of 102 cases were obtained, of which 99% correspond to adverse reactions per medicine and 1% to problems related to medicines. It is concluded that the drug presents a great variety of adverse events, among which the most relevant and those that occur most frequently are: headache, leukopenia, pruritus, diminished therapeutic response and lack of effect, on the other hand the seriousness of the The cases reported are of a non-serious-moderate nature, as the patients required intervention by health personnel and an increase in hospitalization.

• Autores: Pérez Pinzón, Andrea Milena; García Valencia, Diana Isabel
• Tipo de recurso: Trabajo de grado de pregrado
• Fecha de publicación: 2017
• Institución: Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
• Repositorio: Repositorio Institucional UDCA
• Idioma: spa
• OAI Identifier: oai:repository.udca.edu.co:11158/871
• Acceso en línea: https://repository.udca.edu.co/handle/11158/871
• Palabra clave: Tocilizumab; Efectos adversos; Farmacovigilancia; Tocilizumab -- Efectos secundarios; Medicamentos -- Efectos secundarios
• Rights: closedAccess
• License: Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales